Teplin v. The United States of America et al

Filing 47

ORDER by Judge Haywood S. Gilliam, Jr. GRANTING IN PART AND DENYING IN PART THE UNITED STATES 17 MOTION TO DISMISS AND GRANTING WENDI JOINERS 12 MOTION TO DISMISS. Amended Pleadings due by 5/3/2018. (ndrS, COURT STAFF) (Filed on 3/26/2018)

1
2
3
4

UNITED STATES DISTRICT COURT

5

NORTHERN DISTRICT OF CALIFORNIA

6
7

KRIS TEPLIN,
Plaintiff,

8
v.

9
10

THE UNITED STATES OF AMERICA, et
al.,

11
United States District Court
Northern District of California

Case No.17-cv-02445-HSG

Defendants.

ORDER GRANTING IN PART AND
DENYING IN PART THE UNITED
STATES’ MOTION TO DISMISS AND
GRANTING WENDI JOINER’S
MOTION TO DISMISS
Re: Dkt. Nos. 12, 17

12
Pending before the Court are two motions to dismiss Plaintiff Kris Teplin’s Complaint: one

13
14

by Defendant Wendi Joiner (“Joiner”), Dkt. No. 12, and another by Defendant United States (“the

15

United States”), Dkt. No. 17. For the reasons set forth below, Joiner’s motion is GRANTED, and

16

the United States’ motion is GRANTED IN PART and DENIED IN PART.

17

I.

BACKGROUND

18

A.

19

Plaintiff’s suit arises out of the death of her son, Adam Emmott, who died after overdosing

20
21
22

Factual Allegations

on fentanyl, a powerful narcotic. Dkt. No. 1 (Complaint or “Compl.”) ¶¶ 1-2.
1.

Joiner’s Doctor-Patient Relationship with Emmott

In late 2012, Emmott came into the care of Joiner, id. ¶ 24(a), who at the time was a

23

licensed physician employed by Coastal Health Alliance, id. ¶ 18. Coastal Health Alliance is a

24

“federally-supported medical clinic” within the meaning of the Federally Supported Health

25

Centers Assistance Act, 42 U.S.C. § 233(g). Id. ¶ 17. Soon after Emmott came into her care,

26

Joiner became aware of his history of “abus[ing] opiates.” See id. ¶ 24. She knew, for example,

27

that he “ha[d] been treated for opiate addiction,” id. ¶ 24(a), and in February 2013 observed that

28

he relapsed and spent time in a drug-treatment program, id. ¶ 24(b).

1

On September 21, 2013, Emmott asked Joiner for narcotics to relieve “muscular pain,” a

2

request he supported with an MRI from 2009. Id. ¶ 24(c)-(d). Despite her observation that the

3

MRI was “incomplete,” Joiner provided Emmott with 240 oxycodone pills, 10 fentanyl patches,

4

and three Butrans patches. Id. ¶ 24(d). On October 19, 2013, Emmott’s urine tested positive for

5

drugs beyond those Joiner had provided. Id. ¶ 24(e). As a result, Joiner informed him that the

6

health center would “no longer be able to provide [him] with any controlled substance.” Id. Less

7

than a month later, however, Joiner prescribed 240 oxycodone pills and 10 fentanyl patches to

8

Emmott, and continued to provide him with narcotics through the end of 2013. Id. ¶ 24(f).

9

Joiner next saw Emmott on July 26, 2014, when he “reported having recently been in jail,
and having resumed use of heroin[].” Id. ¶ 24(g). The following month, Joiner gave Emmott a

11
United States District Court
Northern District of California

10

shot of morphine after he reported “buying methadone on the street.” Id. ¶ 24(h). She also told

12

him that she would be willing to provide him with “narcotic pain killers” if he consulted and

13

obtained clearance from a pain management specialist in a way that provided her with “clear

14

guidelines.” Id. ¶¶ 25-26.

15

On December 11, 2014, Emmott met with Dr. Michael Yang, who had a pain management

16

practice. Id. ¶ 27. Yang subsequently wrote to Joiner, communicating “a number of false

17

representations [made by Emmott] to Dr. Yang whose falsity would have been obvious to Joiner.”

18

See id. (detailing claims by Emmott that he “had seen numerous spine surgeons who suggested

19

surgery,” and had been managing his pain with a regimen of fentanyl and oxycodone prescribed

20

by Joiner). Yang deferred to Joiner on the medication question, stating that if she found it

21

appropriate to continue prescribing Emmott narcotics, she could do so. Id. ¶ 28.

22

On December 12, 2014, Joiner prescribed Emmott a month’s supply of fentanyl patches

23

and 240 oxycodone tablets. Id. ¶ 29. Later that month, Emmott’s insurance provider “denied

24

Joiner’s request for payment” for the medication “because Joiner had not attempted to use one of

25

[the insurance provider’s] approved medications before turning to Fentanyl patches.” Id. ¶ 30.

26

Also in December 2014, Plaintiff called Coastal Health Alliance and spoke with the health

27

center’s CEO, Steven Siegel. Id. ¶ 5(b). She warned him that Emmott “was engaging in drug-

28

seeking behavior” and that “Joiner was giving [him] improper and dangerous prescriptions for
2

1

narcotics.” Id.
On January 9, 2015, Emmott requested more fentanyl from Joiner. Id. ¶ 31. “When

2
3

advised that his health plan would not cover [the cost of] the fentanyl, [he] volunteered to pay for

4

[it] out of pocket.” Id. Joiner agreed, and prescribed him a month’s worth of fentanyl patches and

5

240 oxycodone tablets. Id. Two days later, on January 11, 2015, Emmott overdosed on fentanyl

6

and died. Id. ¶ 32.

7

2.

While Emmott was in Joiner’s care, Joiner was also under investigation by the California

8
9

Joiner’s Alleged Misconduct

Medical Board. The investigation “revealed that between October 2013 and October 2014[,]
Joiner wrote 33 fraudulent prescriptions for Xanax, Norco and Adderall under a fake name, and

11
United States District Court
Northern District of California

10

purportedly intended for her fiancé.” Id. ¶ 5(a). Plaintiff also alleges that “Joiner took advantage

12

of [Emmott’s] desire for Fentanyl to obtain Oxycodone for her own use, distribution and sale to

13

others.” Id. ¶ 4; see also id. ¶¶ 6 (alleging “that one of Joiner’s purposes in furnishing [Emmott]

14

with prescription medications was . . . part of a scheme to procure Oxycodone for herself and

15

others”), 36 (alleging that “Joiner prepared fraudulent prescriptions for [Emmott] . . . with the

16

intent to jointly further both [his] interest in obtaining Fentanyl to satisfy his drug addiction and

17

Joiner’s interest in Oxycodone”).
In December 2014, Joiner was arrested for “drunk driving and possession of controlled

18
19

substances.” Id. ¶ 5(c). Law enforcement officers found in her possession “fraudulently-

20

obtained” medication belonging to her fiancé, as well as painkillers she said belonged to her. Id.

21

She pled no contest and entered into a drug diversion program. Id.
In December 2015, Joiner was again arrested. Dkt. No. 40 at 4 (ECF pagination).1 As

22
23

relevant here, she was charged with possession for sale of acetaminophen/codeine (“Count 1”) and

24
25
26
27
28

1

The Court grants Joiner’s request for judicial notice of documents related to her criminal
proceedings in state court. See Dkt. No. 40; U.S. ex rel. Robinson Rancheria Citizens Council v.
Borneo, Inc., 971 F.2d 244, 248 (9th Cir. 1992) (“[W]e ‘may take notice of proceedings in other
courts, both within and without the federal judicial system, if those proceedings have a direct
relation to matters at issue.’”) (citations omitted). The Court further notes Joiner’s representation
that Plaintiff is in agreement that the Court may consider these documents. See Dkt. No. 36 at 2.
All references to Docket Number 40 use ECF pagination.
3

1

possession of fentanyl (“Count 5”). See id. at 4-7. Joiner pled guilty to Count 1 on May 5, 2016.

2

See id. at 9-12. The remaining counts, including Count 5, were dismissed. See id. at 11, 27-28

3

(record of case events); see also id. at 22 (charges, pleas, and dispositions).

4

On March 17, 2016, Joiner surrendered her medical license. Compl. ¶ 19.

5

B.

6

Plaintiff filed the Complaint on April 28, 2017. Dkt. No. 1. On June 27, 2017, Joiner filed

Procedural Posture

7

her motion to dismiss. Dkt. No. 12. Plaintiff filed an opposition on July 10, 2017, Dkt. No. 18,

8

and Joiner replied on July 18, 2017. The United States filed its motion to dismiss on July 7, 2017.

9

Dkt. No. 17. Plaintiff filed an opposition on July 21, 2017, Dkt. No. 20, and the United States

10

replied on July 28, 2017, Dkt. No. 22.
On October 31, 2017, the Court ordered the parties to file supplemental briefing on the

United States District Court
Northern District of California

11
12

issue of its subject matter jurisdiction over Plaintiff’s claim under California’s Drug Dealer

13

Liability Act. Dkt. No. 34. The parties submitted that briefing on November 14, 2017. See Dkt.

14

Nos. 35, 36, 37. On November 15, 2017, the Court ordered the parties to file further supplemental

15

briefing on the issue of Joiner’s May 2016 conviction, and whether that impacted Plaintiff’s

16

standing and Joiner’s potential liability under the Drug Dealer Liability Act. Dkt. No. 38. The

17

parties submitted that briefing on November 29, 2017. See Dkt. Nos. 39, 41.

18

II.

LEGAL STANDARD

19

A.

20

A defendant may move for dismissal on grounds that the court lacks subject matter

Rule 12(b)(1)

21

jurisdiction over the action. Fed. R. Civ. P. 12(b)(1). It is the plaintiff’s burden to establish

22

subject matter jurisdiction. See Ass’n of Am. Med. Colls. v. U.S., 217 F.3d 770, 778-79 (9th Cir.

23

2000); Kokkonen v. Guardian Life Ins. Co. of Am., 511 U.S. 375, 376-78 (1994). “A Rule

24

12(b)(1) jurisdictional attack may be facial or factual.” Safe Air for Everyone v. Meyer, 373 F.3d

25

1035, 1039 (9th Cir. 2004) (citing White v. Lee, 227 F.3d 1214, 1242 (9th Cir. 2000)). A facial

26

attack “asserts that the allegations contained in a complaint are insufficient on their face to invoke

27

federal jurisdiction.” Id. A factual attack “disputes the truth of the allegations that, by themselves,

28

would otherwise invoke federal jurisdiction.” Id.
4

B.

1

Rule 12(b)(6)

Federal Rule of Civil Procedure 8(a) requires that a complaint contain “a short and plain

2
3

statement of the claim showing that the pleader is entitled to relief[.]” A defendant may move to

4

dismiss a complaint for failing to state a claim upon which relief can be granted under Federal

5

Rule of Civil Procedure 12(b)(6). “Dismissal under Rule 12(b)(6) is appropriate only where the

6

complaint lacks a cognizable legal theory or sufficient facts to support a cognizable legal theory.”

7

Mendiondo v. Centinela Hosp. Med. Ctr., 521 F.3d 1097, 1104 (9th Cir. 2008). To survive a Rule

8

12(b)(6) motion, a plaintiff must plead “enough facts to state a claim to relief that is plausible on

9

its face.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007). A claim is facially plausible
when a plaintiff pleads “factual content that allows the court to draw the reasonable inference that

11
United States District Court
Northern District of California

10

the defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009).
In reviewing the plausibility of a complaint, courts “accept factual allegations in the

12
13

complaint as true and construe the pleadings in the light most favorable to the nonmoving party.”

14

Manzarek v. St. Paul Fire & Marine Ins. Co., 519 F.3d 1025, 1031 (9th Cir. 2008). Nonetheless,

15

Courts do not “accept as true allegations that are merely conclusory, unwarranted deductions of

16

fact, or unreasonable inferences.” In re Gilead Scis. Sec. Litig., 536 F.3d 1049, 1055 (9th Cir.

17

2008).
If dismissal is appropriate under Rule 12(b)(6), a court “should grant leave to amend even

18
19

if no request to amend the pleading was made, unless it determines that the pleading could not

20

possibly be cured by the allegation of other facts.” Lopez v. Smith, 203 F.3d 1122, 1130 (9th Cir.

21

2000) (citation and internal quotation marks omitted).

22

III.

DISCUSSION

23

Plaintiff’s claims arise under the Federal Tort Claims Act, 28 U.S.C. §§ 2671 et seq.

24

(“FTCA”).2 She brings three causes of action: (1) wrongful death under the Drug Dealer Liability

25

Act, Cal. Health & Safety Code §§ 11700 et seq. (“the DDLA”), against the United States and

26
2

27
28

Plaintiff alleges that Joiner’s former employer, Coastal Health Alliance, is a federally-supported
medical center under 42 U.S.C. § 233(g). Compl. ¶ 17. Under section 233, a plaintiff seeking to
bring a claim against such a medical center must bring an FTCA action. See 42 U.S.C. § 233(a)
(citing 28 U.S.C. §§ 1346(b), 2672)).
5

1

Joiner; (2) wrongful death based on non-medical negligence against the United States; and (3)

2

wrongful death based on medical negligence against the United States. Additionally, within each

3

cause of action, Plaintiff appears to assert a sub-claim against the United States based on negligent

4

hiring, supervision, employment, and retention.

5

The United States moves to dismiss Plaintiff’s Complaint in its entirety, with the exception

6

of her medical negligence claim in her third cause of action. Joiner moves to dismiss Plaintiff’s

7

DDLA claim as it relates to her. The Court considers each motion in turn.

8
9
10

United States District Court
Northern District of California

11
12

A.

Plaintiff’s Challenged Negligence Claims Are Either Barred by Sovereign
Immunity or Fail to State a Claim.
1.

To the extent Plaintiff’s claims against the United States are based on a
theory of negligent hiring, supervision, employment, and retention,
they fall within the FTCA’s discretionary function exception and are
accordingly barred by the doctrine of sovereign immunity.

In each of her causes of action, Plaintiff asserts against the United States sub-claims for

13

negligent hiring, supervision, employment, and retention. Specifically, she alleges that Siegel, as

14

CEO of Coastal Health Alliance, had a duty to “reasonably supervise persons” like Joiner, “and to

15

intervene when he learned of facts to suggest that” she was “misusing her position . . . in a manner

16

that could be harmful” to patients and their families. Compl. ¶ 55; see also id. ¶¶ 66, 75. Such

17

challenges to a government employee’s supervision of a subordinate are barred by the

18

discretionary function exception to the doctrine of sovereign immunity.

19

“Absent a waiver, sovereign immunity shields the Federal Government and its agencies

20

from suit.” Fed. Deposit Ins. Corp. v. Meyer, 510 U.S. 471, 475 (1994). “Sovereign immunity is

21

jurisdictional in nature,” id., meaning that a party’s failure to establish a waiver of sovereign

22

immunity is properly resolved on a motion to dismiss for lack of subject matter jurisdiction, see

23

Sierra Club v. Whitman, 268 F.3d 898, 905-06 (9th Cir. 2001). The FTCA is one such waiver.

24

Specifically, the FTCA waives the federal government’s immunity from claims arising from

25
26
27
28

the negligent or wrongful act or omission of any employee of the
Government while acting within the scope of his office or
employment, under circumstances where the United States, if a
private person, would be liable to the claimant in accordance with
the law of the place where the act or omission occurred.
28 U.S.C. § 1346(b)(1). “The scope of employment inquiry . . . is defined by the applicable state
6

1

law of respondeat superior.” Nationwide Mut. Ins. Co. v. Liberatore, 408 F.3d 1158, 1163 (9th

2

Cir. 2005).

3

The discretionary function exception, however, limits the FTCA’s waiver of sovereign

4

immunity, and exempts any claim based on a government employee’s “exercise or performance or

5

the failure to exercise or perform a discretionary function or duty on the part of a federal agency or

6

an employee of the government, whether or not the discretion involved be abused.” 28 U.S.C. §

7

2680(a). To determine whether government action falls within the discretionary function

8

exception, the Supreme Court has set forth a two-pronged analysis. First, the challenged conduct

9

must “involve an element of judgment or choice,” as determined by the “nature of the conduct,
rather than the status of the actor.” U.S. v. Gaubert, 499 U.S. 315, 322 (1991) (quoting Berkovitz

11
United States District Court
Northern District of California

10

v. U.S., 486 U.S. 531, 536 (1988); U.S. v. Varig Airlines, 467 U.S. 797, 813 (1984)) (citation,

12

internal quotation marks, and brackets omitted). Second, the judgment of the government

13

employee must be “of the kind that the discretionary function exception was designed to shield.”

14

Id. at 322-23 (quoting Berkovitz, 486 U.S. at 536). Given the exception’s purpose—to “prevent

15

judicial second-guessing of legislative and administrative decisions grounded in social, economic,

16

and political policy” through a tort action—courts construe it as “protect[ing] only governmental

17

actions and decisions based on considerations of public policy.” Id. (quoting Berkovitz, 486 U.S.

18

at 537). The “focus of the inquiry,” then, is whether the “nature of the actions taken,” pursuant to

19

an exercise of discretion, “are susceptible to policy analysis.” Id. at 325.

20

Because the United States does not appear to dispute that Siegel’s conduct fell within the

21

scope of his employment, and thus within the FTCA, the Court turns to the discretionary function

22

exception inquiry.

23
24

a.

Siegel’s management of Joiner involved an element of judgment
or choice.

25

The parties are in agreement that Siegel’s alleged duty to “supervise” Joiner and

26

“intervene” if necessary involves an element of judgment or choice, and thus satisfies the first

27

prong of the discretionary function inquiry. See Dkt. No. 17 at 8; Dkt. No. 20 at 3. The Court

28

agrees. The Supreme Court has held that where “a federal statute, regulation, or policy
7

1

specifically prescribes a course of action for an employee to follow,” no element of judgment or

2

choice can be shown. Gaubert, 499 U.S. at 322 (quoting Berkovitz, 486 U.S. at 536) (internal

3

quotation marks omitted). Here, however, Plaintiff has not alleged the existence of such a statute,

4

regulation, or policy. See Lu v. Powell, 621 F.3d 944, 950 (9th Cir. 2010) (affirming dismissal

5

because discretionary function exception shielded federal agency’s decision not to discipline an

6

asylum officer where plaintiffs had not “identified any mandatory duty to discipline” that officer).

7

Moreover, the nature of Siegel’s position as CEO plainly involved an element of judgment or

8

choice in managing subordinates. See Patterson v. Kelso, No. 2:16-cv-0719 AC P, 2016 WL

9

4126726, at *6 (E.D. Cal. Aug. 2, 2016) (dismissing prisoner’s negligent hiring, retention, and
supervision claims against the receiver for the California prison healthcare system because “while

11
United States District Court
Northern District of California

10

defendant may have a duty to supervise medical personnel, how he chooses to carry out that duty

12

. . . is left to his discretion”).

13
14
15

b.

Siegel’s management of Joiner involved the type of duty that the
discretionary function exception was meant to shield.

The parties diverge with regard to the second prong: whether Siegel’s alleged duty to

16

supervise Joiner is “the kind that the discretionary function exception was designed to shield.”

17

See Gaubert, 499 U.S. at 322-23. The Court finds that it is.

18

“[D]ecisions relating to the hiring, training, and supervision of employees usually involve

19

policy judgments of the type Congress intended the discretionary function to shield.” Vickers v.

20

U.S., 228 F.3d 944, 950 (9th Cir. 2000); see also Nurse v. U.S., 226 F.3d 996, 1001 (9th Cir. 2000)

21

(finding, in FTCA action, that defendants’ “allegedly negligent and reckless employment,

22

supervision, and training . . . [fell] squarely within the discretionary function exception”). The

23

underlying question is whether the decision or action at issue is “susceptible to policy analysis.”

24

See Gaubert, 499 U.S. at 325. This requires consideration of whether the government entity

25

“balanced competing public policy concerns in reaching its decision.” See Gager v. U.S., 149

26

F.3d 918, 921 (9th Cir. 1998).

27
28

On the facts alleged, the Court concludes that Siegel’s decisions in hiring, supervising, and
retaining Joiner are susceptible to policy analysis, and thus were intended to fall within the
8

discretionary function exception.3 Other examples of conduct found to be susceptible to policy

2

analysis include decisions on how to prioritize “which termination [of employment]

3

recommendations to review when and in what order,” see Vickers, 228, F.3d at 951, and the

4

decision by the U.S. Postal Service to limit “training and supervision in mail bomb detection” to

5

places “where a known threat existed,” see Gager, 149 F.3d at 921. It makes sense that Siegel’s

6

decisions regarding the continued employment of a doctor at a federal health clinic would also

7

involve “balanc[ing] competing public policy concerns,” such as resource allocation, the handling

8

of patient complaints, and the importance of addressing a disciplinary issue with a practitioner.

9

Plaintiff’s argument to the contrary is unpersuasive. In support of her argument that the

10

discretionary function exception does not apply, Plaintiff cites Brock v. U.S., 64 F.3d 1421 (9th

11
United States District Court
Northern District of California

1

Cir. 1995), and Bennett v. U.S., 803 F.2d 1502 (9th Cir. 1986). Both are inapposite. In Brock, the

12

Ninth Circuit affirmed the holding in Bennett that “the assault and battery exception [to the FTCA,

13

28 U.S.C. § 2680(h)] does not immunize the Government from liability for negligently hiring and

14

supervising an employee.” 64 F.3d at 1425; see also Bennett, 803 F.2d at 1503. Plaintiff contends

15

that these holdings “clearly authorize[]” her negligent hiring, supervision, employment, and

16

retention sub-claims. See Dkt. No. 20 at 3. But Brock and Bennett are narrow in scope, and

17

govern only those negligent hiring and supervision claims where the injury stems from a federal

18

employee’s assault or battery. The Court declines to extend this principle in this case, given that

19

Plaintiff does not allege assault or battery.
Moreover, Plaintiff mischaracterizes the holding in Vickers in asserting that “the decision

20
21

whether or not to investigate [a shooting between a government employee and his ex-wife] was

22

not [within the discretionary function exception].” See Dkt. No. 20 at 5. While Vickers did so

23

hold, that was because “the failure to report or investigate . . . constituted a failure to follow the

24

mandatory requirements proscribed by agency regulations as implemented by policy guidelines.”

25
26
27
28

3

Plaintiff alleges that she called Siegel in December 2014 to inform him that “Joiner was giving
[her son] improper and dangerous prescriptions for narcotics,” Compl. ¶ 5(b), and strongly implies
that Siegel took no subsequent action. This does not change the Court’s analysis, because
“negligence in performing discretionary functions is not actionable.” See Vickers, 228 F.3d at 950
(citing Varig Airlines, 467 U.S. at 811).
9

1

228 F.3d at 953 (emphasis added). In other words, the agency in that case failed to satisfy the first

2

prong of the discretionary function inquiry, because there is no element of choice or judgment

3

where there is an on-point regulatory mandate.

4

Accordingly, the Court grants the United States’ motion as to Plaintiff’s sub-claims of

5

negligent hiring, supervision, employment, and retention because they fall within the discretionary

6

function exception to the doctrine of sovereign immunity. They are thus outside this Court’s

7

subject matter jurisdiction.

8
9
10

2.

Plaintiff’s wrongful death claim based on a theory of “non-medical
negligence” fails to state a plausible claim.

Plaintiff styles her second cause of action as “wrongful death based on non-medical

United States District Court
Northern District of California

11

negligence,” Compl. at 11 (section heading), compared to the medical negligence alleged in her

12

third cause of action. The United States argues that the “gravamen” of this claim “is medical

13

negligence and should be construed as such.” See Dkt. No. 17 at 9. Plaintiff, in turn, cites Federal

14

Rule of Civil Procedure 8(d)(3) for the proposition that “[a] party may state as many separate

15

claims or defenses as it has, regardless of consistency.” Dkt. No. 20 at 7 (original emphasis).

16

While Plaintiff “may, of course, plead more than one legal theory in the alternative,” she

17

“should provide plausible facts that support each theory.” See Coffen v. Home Depot U.S.A. Inc.,

18

No. 16-cv-03302-PJH, 2016 WL 4719273, at *6 (N.D. Cal. Sept. 9, 2016). Plaintiff has failed to

19

do so. While the United States appears to concede that Plaintiff has adequately pled a claim of

20

medical negligence, she fails to allege sufficient facts in support of any other variant of a

21

negligence claim. All of the facts alleged by Plaintiff regarding Joiner and Emmott’s relationship

22

have to do with Joiner’s conduct in her role as Emmott’s physician. Plaintiff’s sole attempt at

23

differentiating Joiner’s alleged medical and non-medical negligence is a wholly conclusory

24

assertion that, as to the latter, “Joiner’s conduct . . . was undertaken for a purpose other than

25

delivering medical care.” Id. ¶ 65. Such an assertion, without supporting factual allegations, is

26

insufficient to state a negligence claim stemming from conduct other than that undertaken by

27

Joiner in her professional role.

28

Accordingly, the Court grants the United States’ motion as to Plaintiff’s claim for non10

1

medical negligence.
Plaintiff’s Claim Under the DDLA Survives in Part.

2

B.

3

Plaintiff asserts her DDLA claim against the United States “and, to the extent this cause of

4

action cannot be brought under the FTCA,” against Joiner “in her individual capacity.” Compl. at

5

9.

6
7

The DDLA is a California statute intended “to provide a civil remedy for damages to
persons in a community injured as a result of the use of an illegal controlled substance,” and
enables plaintiffs “to recover damages from those persons in the community who have joined the

8

marketing of illegal controlled substances.” Cal. Health & Safety Code § 11701. As a

9

preliminary matter, the Court finds that it has supplemental jurisdiction over Plaintiff’s DDLA
claim. It is sufficiently related to her negligence claims such “that they form part of the same case

11
United States District Court
Northern District of California

10

or controversy under Article III of the United States Constitution.” See 28 U.S.C. § 1367(a). The

12
13
14
15

Court notes that, as described below, this case poses a novel issue of state law regarding the
relationship between two DDLA provisions, which is a ground upon which this court “may decline
to exercise supplemental jurisdiction.” See id. § 1367(c)(1) (emphasis added). Still, given the
unique posture of this case—and the permissive language of section 1367(c)—the Court elects to
exercise its supplemental jurisdiction over this claim.4

16

1.

17
18

The United States fails to meet its burden of showing that Plaintiff’s
DDLA claim should be dismissed.

Plaintiff confirmed at a status conference, see Dkt. No. 46, that her DDLA claim against

19

the United States is not solely dependent on a theory of negligent hiring, supervision, employment,

20

and retention. At the same hearing, the United States acknowledged that it did not move to

21

dismiss the DDLA claim on any other ground. Thus, at this juncture, it is unclear what—if

22

anything—remains of Plaintiff’s DDLA claim against the United States now that the negligent

23

hiring, supervision, employment, and retention sub-claim has been dismissed. More

24

fundamentally, Plaintiff has cited no legal authority that would allow her to assert a DDLA claim

25
26
27
28

4

The Court is cognizant of the potential comity concerns that arise when a federal court decides
novel issues of state law. All parties in this case, however, are in agreement that the Court may
properly exercise supplemental jurisdiction here. See Dkt. Nos. 35, 36, 37. Moreover, given that
this Court has exclusive jurisdiction over Plaintiff’s DDLA claim against the United States, the
convenience of the parties favors keeping the entire action in a single forum.
11

1

directly against the federal government. The latter circumstances notwithstanding, however, the

2

United States did not meaningfully address any of these points in its moving papers, and thus

3

failed to meet its burden of showing that the claim should be dismissed on the pleadings.

4

Accordingly, to the extent Plaintiff’s DDLA claim against the United States is not

5

premised on a theory of negligent hiring, supervision, employment, and retention, the United

6

States’ motion is denied. This denial does not preclude the government from seeking summary

7

judgment as to this claim.

8

2.

9
10

Plaintiff either lacks standing to bring a DDLA claim against Joiner or
that claim is time-barred.

As for Plaintiff’s DDLA claim against Joiner, Joiner contends that Plaintiff lacks standing

United States District Court
Northern District of California

11

to bring a DDLA claim, and that such a claim would be untimely in any event. Alternatively,

12

Joiner argues that Plaintiff fails to state a claim under the DDLA. Because the Court agrees with

13

Joiner’s standing and timeliness arguments, it need not reach the question of whether Plaintiff

14

states a claim.

15
16

a.

The DDLA’s statute of limitations applies to Plaintiff’s claim.

Joiner first argues that Plaintiff’s claim is governed by section 340.5 of the California Code

17

of Civil Procedure. See Dkt. No. 12 at 5. Under that provision, which establishes a limitations

18

period for wrongful death actions based on professional negligence, “the time for the

19

commencement of action shall be three years after the date of injury or one year after the plaintiff

20

discovers, or through the use of reasonable diligence should have discovered, the injury,

21

whichever occurs first.” Cal. Civ. Proc. Code § 340.5. Plaintiff argues that section 340.5 does not

22

apply to actions under the DDLA, because “furnishing opiates to a known opiate addict” does not

23

fall within the ambit of professional negligence. See Dkt. No. 18 at 3.

24

The Court agrees that the statute of limitations for medical malpractice actions set forth in

25

the California Code of Civil Procedure does not govern Plaintiff’s DDLA claim, but for a different

26

reason than posited by Plaintiff. The DDLA has its own limitations provision, and “a specific

27

statute of limitations takes precedence over a general one, even though the latter would be broad

28

enough to include the subject to which the more particular provision relates.” See Vafi v.
12

1

McCloskey, 193 Cal. App. 4th 874, 880 (2011) (citation and internal quotation marks omitted); see

2

also Sisseton-Wahpeton Sioux Tribe of Lake Traverse Indian Reservation, N.D & S.D. v. U.S., 895

3

F.2d 588, 594 (9th Cir. 1990) (“We agree that when legislation contains its own statute of

4

limitations, the more specific limitation preempts a more general statute of limitations.”) (citation

5

omitted). Accordingly, the Court turns to the DDLA itself to determine the applicable limitations

6

period.

7
8
9

b.

The Court must resolve a novel question of state law to
determine whether Plaintiff has standing or is time-barred from
bringing a DDLA claim against Joiner.

Joiner next argues that Plaintiff either lacks standing or is time-barred from bringing a
claim against her under the DDLA, an assertion with which Plaintiff disagrees. At the heart of

11
United States District Court
Northern District of California

10

their dispute is a novel question regarding the relationship between the DDLA’s standing

12

provisions and its statutes of limitations.

13

i.

14
15

The DDLA does not detail the intended relationship
between its standing provisions and its statute of
limitations provisions.

The DDLA confers standing to sue on several categories of plaintiffs. See Cal. Health &

16

Safety Code § 11705. As relevant here, the parent of a controlled substance user may seek

17

damages under the DDLA from:

18
19
20
21
22
23
24
25
26
27
28

(1) A person who sold, administered, or furnished an illegal
controlled substance to the individual user of the illegal controlled
substance.
(2) A person who knowingly participated in the marketing of illegal
controlled substances, if all of the following apply:
(A) The place of illegal activity by the individual user of an
illegal controlled substance is within the city, city and
county, or unincorporated area of the county in which the
defendant’s place of participation is situated.
(B) The defendant’s participation in the marketing of illegal
controlled substances was connected with the same type of
specified illegal controlled substance used by the individual
user of an illegal controlled substance, and the defendant has
been convicted of an offense for that type of specified illegal
controlled substance.
(C) The defendant participated in the marketing of illegal
controlled substances at any time during the period the
13

individual user of an illegal controlled substance illegally
used the controlled substance.

1
2

(D) The underlying offense for the conviction of the
specified illegal controlled substance occurred in the same
county as the individual user’s place of use.

3
4

Cal. Health & Safety Code § 11705(b). Moreover, all DDLA claims are subject to one of two

5

limitations periods:

6

(a) Except as otherwise provided in this section, a claim under this
division shall not be brought more than one year after the defendant
furnishes the specified illegal controlled substance. . . .

7
8

(b) For a defendant, the statute of limitations under this section does
not expire until one year after the individual potential defendant is
convicted of a criminal offense involving an illegal controlled
substance or as otherwise provided by law.

9
10

United States District Court
Northern District of California

11

Id. § 11714. The DDLA does not detail the intended relationship between the provisions in

12

section 11705(b) and those in section 11714.

13

ii.

14

Read together, the DDLA’s standing provisions and
statute of limitations are determinative of Plaintiff’s
claim against Joiner.

15

Joiner contends that because she “was a physician who directly prescribed the controlled

16

substance that the decedent used,” see Dkt. No. 12 at 9, Plaintiff could have standing to sue only

17

under section 11705(b)(1), which in turn triggers the limitations period in section 11714(a), see

18

Dkt. No. 39 at 3. Under section 11714(a), a cause of action accrues when a claimant “has reason

19

to know” that a person was harmed due to that person’s use of an “illegal controlled substance.”5

20

Plaintiff does not dispute Joiner’s contention that her DDLA claim accrued on January 11, 2015,

21

when Emmott is alleged to have died of a fentanyl overdose. Thus, Joiner concludes that under

22

section 11714(a), the limitations period expired a year later, on January 11, 2016—more than a

23

year before Plaintiff filed this action on April 28, 2017.
Plaintiff appears to assert that she has standing to bring a DDLA claim under section

24
25

11705(b)(2), as opposed to section 11705(b)(1). See Dkt. No. 18 at 4. Applying that provision,

26
27
28

5

For purposes of analyzing the timeliness issue, the Court assumes without deciding that the drugs
allegedly prescribed by Joiner to Plaintiff were “illegal controlled substances” within the meaning
of the statute.
14

1

Plaintiff argues that because Joiner was convicted of possession of narcotics with intent to sell on

2

May 5, 2016, see Compl. ¶ 5(h), the statute of limitations—per section 11714(b)—actually expired

3

a year after that, on May 5, 2017, shortly after Plaintiff filed the Complaint, see Dkt. No. 18 at 4.

4

In response, Joiner contends that the limitations period in section 11714(b) does not apply,

5

because Plaintiff does not meet the requirements for standing under section 11705(b)(2). See Dkt.

6

No. 39 at 2. Specifically, Joiner argues that in order for her conviction to serve as a basis for

7

standing under section 11705(b)(2)(B), it had to involve fentanyl, i.e., the same drug which caused

8

Emmott’s death. See id. at 2-3. Joiner, however, was convicted only for possession for sale of

9

acetaminophen and codeine—not fentanyl. See Dkt. No. 40 at 4-7, 27-28.
Plaintiff appears to counter that she can mix and match, so to speak, the DDLA’s standing

10

United States District Court
Northern District of California

11

and statute of limitations provisions, disagreeing with Joiner’s contention that section 11714(b)

12

applies only to defendants who do not directly furnish an illegal controlled substance, as described

13

in section 11705(b)(1). See Dkt. No. 18 at 5. And indeed, if Plaintiff could assert standing under

14

section 11705(b)(1) and invoke the limitations period in section 11714(b), her claim likely would

15

be timely. That is to say, if she brought suit under section 11705(b)(1) because Joiner “furnished”

16

Emmott with fentanyl, but was subject to section 11714(b), the deadline for filing suit would be

17

“one year after the individual potential defendant is convicted of a criminal offense involving an

18

illegal controlled substance.” Plaintiff could then argue that Joiner’s May 5, 2016 drug conviction

19

meets the requirement of section 11714(b), which would push her filing deadline to May 5,

20

2017—days after she filed this Complaint. Joiner, for her part, says that because Joiner “directly

21

prescribed the controlled substance” used by Emmott, section 11714(a) applies. See Dkt. No. 12

22

at 9.

23

The determinative issue in deciding which statute of limitations applies, therefore, is

24

whether the standing provisions within section 11705(b) are somehow related to the limitations

25

period provisions within section 11714. Put differently, the question is whether the DDLA claim

26

of a plaintiff suing a defendant described in section 11705(b)(1) is necessarily governed by the

27

limitations period in section 11714(a), while the DDLA claim of a plaintiff suing a defendant

28

described in section 11705(b)(2) is likewise governed by section 11714(b)(2)—or, if a plaintiff
15

1

may simply invoke whichever standing provision and limitations period works best for her DDLA

2

claim.

3

iii.

4

Plaintiffs who sue under the DDLA may not mix and
match the statute’s standing provisions and limitations
periods.

5

This Court must decide whether plaintiffs can mix and match the DDLA’s standing

6

provisions and limitations periods. Based on the facts as alleged, Plaintiff’s claim survives only if

7

such mixing and matching is permissible under the statute. The Court finds that it is not.

8

Because the California Supreme Court has not decided this novel question of state law, this

9

Court’s task “is to predict how the state high court would resolve it.” Hayes v. Cnty. of San Diego,
658 F.3d 867, 871 (9th Cir. 2011) (quoting Westlands Water Dist. v. Amoco Chem. Co., 953 F.2d

11
United States District Court
Northern District of California

10

1109, 1111 (9th Cir. 1991)). This does not mean the Court is “free to reject” an on-point ruling by

12

a lower state court “merely because it has not received the sanction of the state’s highest court.”

13

Id. at 871-72 (quoting Katz v. Children’s Hosp., 28 F.3d 1520, 1528-29 (9th Cir. 1994)). Rather,

14

“[a]n intermediate state appellate court decision is a ‘datum for ascertaining state law which is not

15

to be disregarded by a federal court unless it is convinced by other persuasive data that the highest

16

court of the state would decide otherwise.’” Id. at 872 (quoting Estrella v. Brandt, 682 F.2d 814,

17

817 (9th Cir. 1982)).
Here, the Court has found only one opinion by the California Court of Appeal that

18
19

provides a “datum for ascertaining state law”: Barker v. Garza, 218 Cal. App. 4th 1449 (2013),

20

which was decided by a 2-1 margin and included a thoroughly-reasoned dissenting opinion. In

21

Barker, the plaintiff brought a DDLA claim against her deceased brother’s nurse, who was alleged

22

to have illegally provided him with fentanyl and Klonopin, the combination of which resulted in

23

his death. 218 Cal. App. 4th at 1452. The issue was whether the statute of limitations in section

24

11714(a) was tolled by the California Code of Civil Procedure’s minority tolling provision until

25

the plaintiff reached the age of majority. Id. at 1453.6 In reaching its conclusion that California’s

26
6

27
28

The court in Barker also considered whether section 11714(b) “tolled [the plaintiff’s] claim until
the expiration of the time in which [the defendant] could have been prosecuted for controlled
substance offenses.” 218 Cal. App. 4th at 1453. It devoted only one paragraph to this issue,
however, deeming it waived and finding nothing in the record to suggest that the defendant was
16

1

minority tolling provision did not apply to DDLA claims, the court cast section 11714(b) as a

2

“tolling provision,” from which it could “infer legislative intent to exclude all other grounds for

3

tolling.” See id. at 1460 (internal quotation marks omitted). On this point, the Barker majority

4

disagreed with the characterization of section 11714(b) as “an enlarged limitations period

5

applicable to only certain defendants”:
[i]n the dissent’s view, [sections 11703, 11704, and 11705]
“distinguish[] two groups of potential civil defendants: (1) [t]hose
who sell or furnish drugs to an individual user; and (2) those who
participate in other marketing activities by requiring that the latter
have been convicted of a drug offense arising from their
participation.” . . . That is correct, but we disagree that distinction
carries over to Health and Safety Code section 11714, with
subdivision (a) only applying to the former category of individuals,
and subdivision (b) only applying to the latter.

6
7
8
9
10

United States District Court
Northern District of California

11

Id. at 1461 (citation omitted). The court provided two reasons. First, it wrote, “both categories of
defendants”—i.e., those described in both sections 11705(b)(1) and (2)—“can ‘furnish’ controlled

12
substances to trigger the statute of limitations in section 11714[(a)].” Id. Second, the language of
13
14
15
16
17
18
19
20
21
22
23
24

section 11714(b) is “broad, applying to ‘a defendant’ and covering any ‘criminal offense involving
an illegal controlled substance’ . . . which could very well include convictions for the direct sale or
furnishing of an illegal controlled substance.” Id. Likewise, the “individual potential defendant”
in section 11714(b) “could be any defendant liable under the DDLA, whether as a market
participant or a direct seller, but who has not yet been named in the lawsuit.” Id. at 1461-62.
Accordingly, it concluded that section 11714(b) “is no more than a tolling provision applying to
all defendants under the DDLA.” Id. at 1462.
The dissent disagreed with the majority’s characterization of section 11714(b) as a “tolling
provision,” see id. at 1468, instead describing it as an exception to the general rule set forth in
section 11714(a), and finding that this exception “creates . . . an enlarged limitations period
applicable to only certain defendants,” id. at 1469. Noting that the two “competing provisions” of
section 11714 “seem confusing and contradictory,” the dissent nevertheless found a “reasonable

25
construction . . . by examining them against other provisions” of the DDLA. Id. at 1470. Starting
26

with section 11705(b), the dissent noted that “an action may not be brought against one who did

27
28

ever prosecuted or convicted. Id. at 1462-63.
17

1

not furnish the drug but instead knowingly participated in the marketing of illegal controlled

2

substances under [section 11705(b)(2)] unless certain conditions are met.” Id. In this way, the

3

DDLA “distinguishes two groups of potential civil defendants: (1) Those who sell or furnish drugs

4

to an individual user and (2) those who participate in other marketing activities by requiring that

5

the latter have been convicted of a drug offense arising from their participation.” Id. at 1470-71

6

(emphasis added). The statutes of limitations, the dissent reasoned, “make[] a similar distinction.”

7

See id. at 1471. That is,

8
9
10

United States District Court
Northern District of California

11
12
13
14
15

the one-year time period of [section 11714(a)] applies to defendants
who actually furnished the drug, as to whom no conviction is
required as a predicate to liability under the Act. [Section 11714(b)]
applies a differently calibrated one-year limitations period to
“individual potential defendant[s],” which I believe refers to
defendants whose liability under the Act is based on marketing
participation activities apart from selling or furnishing drugs to the
individual user. Because a conviction for a drug-related offense
arising from their marketing participation activities is a condition
precedent to liability under the Act, this subdivision sets them apart
as potential defendants by providing a one-year limitations period
that runs from the date of any conviction. This makes sense because
until and unless such potential defendants are convicted, they cannot
be held liable under the Act.

16

Id. (original emphasis). Thus, the point of section 11714(b) “is to create a different limitations

17

period for claims against a subcategory of potential defendants.” Id. (emphasis added).

18

The Court finds the dissent’s analysis persuasive, and believes the California Supreme

19

Court would agree. On its face, section 11705(b) distinguishes between two sub-groups of

20

defendants who are subject to liability under the DDLA: those who (as relevant here) directly

21

furnish illegal drugs to a claimant’s relative, and those who knowingly participate in the marketing

22

of illegal drugs in some way other than directly furnishing drugs to such a person. This is

23

consistent with the broadly-worded purpose of the statute, which aims in part to enable claimants

24

“to recover damages from those persons in the community who have joined the marketing of

25

illegal controlled substances.” See Cal. Health & Safety Code § 11701. Moreover, it is most

26

logical to carry this reasoning over to section 11714, the language of which tracks section

27

11705(b): for those defendants who have directly furnished the drug to a person related to the

28

claimant, section 11714(a) applies; for those defendants who have knowingly participated in the
18

1

marketing of illegal drugs in some other way within the meaning of the statute, section 11714(b)

2

describes the applicable limitations period, based on the date of the defendant’s qualifying

3

conviction.

4

The Court respectfully disagrees that the California Supreme Court would adopt the

5

reasoning of the majority opinion in Barker. First, the Court disagrees with the majority’s

6

conclusion that section 11714(b) is a tolling provision, rather than an exception to section

7

11714(a): the provision does not use the word “toll,” nor does it mention or refer to the concept of

8

equitable relief from an otherwise-applicable statute of limitations. Further, the Court believes the

9

majority’s analysis of the relationship between sections 11705 and 11714(b) is difficult to
reconcile with the language of those provisions. Specifically, the majority’s reasoning that section

11
United States District Court
Northern District of California

10

11714(a) applies to both categories of defendants in section 11705(b), because both categories can

12

furnish controlled substances, overlooks a key difference between sections 11705(b)(1) and (2):

13

under section 11705(b)(1), a DDLA defendant has to sell, administer, or otherwise furnish drugs

14

to an “individual user” who, as relevant here, is related to the claimant. Under section

15

11705(b)(2), however, the defendant need only furnish drugs to someone in the individual user’s

16

community. The limitations periods in section 11714 reflect this distinction: section 11714(a)

17

references “the harm from use of an illegal substance,” indicating a textual connection to section

18

11705(b)(1). Section 11705(b)(2), rather than requiring such “harm from use,” addresses the harm

19

that results when a defendant sells or otherwise furnishes the same drug used by an individual user

20

in the same geographic area, during the same time period. Section 11705(b)(2)’s additional

21

requirement that a defendant have been convicted for such drug-dealing activity provides a clear

22

textual connection to section 11714(b).

23

Because the California Supreme Court has not yet decided the nature of the relationship

24

between sections 11705(b) and 11714 of the DDLA, this Court is obligated to try to predict the

25

conclusion it would reach, while giving due deference to the California Court of Appeal’s decision

26

in Barker. See Hayes, 658 F.3d at 867, 871. In this case, while the decision of the majority in

27

Barker is a “datum for ascertaining state law,” the Court is convinced by the “persuasive data” and

28
19

1

reasoning in the dissent that the California Supreme Court “would decide otherwise.” 7 See id. at

2

872. This is especially true given that the Barker court said that it was “address[ing] only two

3

narrow issues,” neither of which was identical to the question confronting the Court in this case.

4

Cf. Barker, 218 Cal. App. 4th at 1453. Accordingly, this Court finds that under the DDLA,

5

plaintiffs may not simply invoke whichever standing provision and statute of limitations is most

6

favorable for them: section 11714(a) governs claims against the defendants described in section

7

11705(b)(1), and section 11714(b) governs claims against the defendants described in section

8

11705(b)(2).

9

iv.

10

Considering Plaintiff’s DDLA claim against Joiner in light of the analysis above, it is clear

United States District Court
Northern District of California

11
12

Plaintiff either lacks standing to sue Joiner under the
DDLA or is time-barred from bringing a claim.

that either she lacks standing, or her claim is untimely.
If Plaintiff brings her DDLA claim under section 11705(b)(1), on the grounds that Joiner

13
14

“sold, administered, or furnished an illegal controlled substance” to Emmott, then section

15

11714(a) governs her case. Plaintiff does not dispute that her claim accrued on January 11, 2015,

16

the day of Emmott’s death. Plaintiff was therefore required to bring her claim no later than one

17

year later, on January 11, 2016. Because she filed this action on April 28, 2017, Plaintiff’s claim

18

is time-barred.
Alternatively, if Plaintiff seeks to bring her claim under section 11705(b)(2), on the

19
20

grounds that Joiner “knowingly participated in the marketing of an illegal controlled substance,”

21
22
23
24
25
26
27
28

7

The dissent’s interpretation was further “bolstered by a fuller examination of the Act’s legislative
history.” Barker, 218 Cal. App. 4th at 1471. The dissent noted that when the DDLA was first
introduced in February 1996, the initial iteration of section 11714(b) stated: “‘[f]or a plaintiff, the
statute of limitations under this section is tolled . . .’ while the plaintiff was incapacitated by his
use of illegal drugs, and, for a defendant, the statute of limitations ‘[was] tolled’ until six months
after his conviction of a drug offense.” Id. at 1471-72 (quoting Sen. Bill No. 1754 (1995-1996
Reg. Sess.) as introduced Feb. 22, 1996) (original emphasis, brackets, and ellipses). Later, the
tolling language “was deleted and replaced with language that enlarged the limitations period for
certain defendants.” Id. at 1472. In light of the principle that “[l]egislative rejection of specific
language in an act as originally introduced is persuasive evidence the act should not be construed
to include the omitted language,” id. at 1471 (citing Conservatorship of Bryant, 45 Cal. App. 4th
117, 130 (1996), the dissent persuasively reasoned that the California legislature “did not intend
[section 11714(b)] to serve as a tolling provision,” see id. at 1472.
20

1

she must show that: (1) Emmott used an illegal controlled substance within the “city, city and

2

county, or unincorporated area of the county” in which Joiner’s “place of participation is situated”;

3

(2) Joiner’s “participation in the marketing of illegal controlled substances was connected with the

4

same type of specified illegal controlled substance” used by Emmott, and Joiner “has been

5

convicted of an offense for that type of specified illegal controlled substance”; (3) Joiner

6

“participated in the marketing of illegal controlled substances at any time during the period”

7

Emmott used a controlled substance; and (4) “[t]he underlying offense for the conviction of the

8

specified illegal controlled substance occurred in the same county” in which Emmott used a

9

controlled substance. Plaintiff argues that Joiner’s conviction on May 5, 2016 is a conviction
within the meaning of section 11705(b)(2)(B). See Cal. Health & Safety Code § 11705(b)(2)(A)-

11
United States District Court
Northern District of California

10

(D). But Emmott died of a fentanyl overdose, see Compl. ¶ 32, and Joiner’s conviction was for

12

possession for sale of acetaminophen and codeine, see Dkt. No. 40 at 4-7, 27-28. The language of

13

section 11705(b)(2) is clear: Joiner’s participation in the marketing of illegal drugs must be

14

“connected with the same type of specified illegal controlled substance” used by Emmott, and she

15

must “[have] been convicted of an offense for that type for specified illegal controlled substance.”

16

See Cal. Health & Safety Code § 11705(b)(2)(B) (emphasis added). Thus, because Plaintiff is

17

suing to recover for her son’s fatal fentanyl overdose, she cannot sue Joiner under section

18

11705(b)(2) on the basis of her conviction for possession for sale of acetaminophen and codeine.

19
20
21
22
23

Plaintiff thus is either time-barred from bringing a DDLA claim against Joiner or lacks
standing to do so. Joiner’s motion is accordingly granted.
C.

Plaintiff Is Granted Leave to Amend Her Wrongful Death Claim Based on
Non-Medical Negligence and Her DDLA Claim Against Joiner.

The Court will grant leave to amend “unless it determines that the pleading could not

24

possibly be cured by the allegation of other facts.” Lopez, 203 F.3d at 1130 (citation omitted).

25

Accordingly, the Court grants Plaintiff leave to amend the claim she styles as one for wrongful

26

death based on “non-medical negligence.” While Plaintiff failed to plead facts supporting such a

27

cause of action—particularly in conjunction with her claim based on medical negligence—the

28

Court cannot say at this juncture that it would be impossible for Plaintiff to do so. The same is
21

1

true of Plaintiff’s DDLA claim against Joiner, for which the Court also grants leave to amend. If

2

Plaintiff can truthfully plead facts showing that she has standing to sue Joiner under section

3

11705(b)(2), that may render her claim timely under section 11714(b).
Leave to amend is denied, however, as to Plaintiff’s claims of negligent hiring,

4
5

supervision, employment, and retention against the United States. The Court is satisfied there are

6

no additional facts Plaintiff could plead to show that those claims are not barred by sovereign

7

immunity.

8

IV.

9
10

CONCLUSION
For the foregoing reasons, the Court rules as follows:
The United States’ motion is GRANTED IN PART and DENIED IN PART. Plaintiff’s

United States District Court
Northern District of California

11

sub-claims of negligent hiring, supervision, employment, and retention against the United States

12

are DISMISSED WITH PREJUDICE. Plaintiff’s wrongful death claim based on non-medical

13

negligence against the United States is DISMISSED WITH LEAVE TO AMEND. The United

14

States’ motion is DENIED as to Plaintiff’s DDLA claim, to the extent it is not predicated on the

15

sub-claim of negligent hiring, supervision, employment, and retention.

16
17
18

Joiner’s motion is GRANTED, and Plaintiff’s DDLA claim as to her is DISMISSED
WITH LEAVE TO AMEND.
Should Plaintiff choose to amend the Complaint as to her wrongful death claim based on

19

non-medical negligence and her DDLA claim, she is directed to do so in accordance with the

20

discussion above no later than 28 days from the date of this Order.

21
22

IT IS SO ORDERED.
Dated: 3/26/2018

23
24
HAYWOOD S. GILLIAM, JR.
United States District Judge

25
26
27
28
22